2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Newborn Screening, Omics Technologies, Pathology, Serologic Tests, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Surgical, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, APL, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

6096 Automated label-free raman scatter spectroscopy enables routine longitudinal T- and B-cell monitoring in B-cell non-Hodgkin lymphoma

Ben Zion Katz, PhD, Chen Glait Santar, PhD2, Tanya Badelbayev3, Adam Seegmiller, MD, PhD4, Claudio Mosse, MD PhD5, Olga Pozdnyakova, MD, PhD6, Michael Feldman, MD PhD7, Irit Avivi Mazza, MD8
1 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel
2 Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel
3 Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel
4 Vanderbilt University Medical Center,, Nashville, United States
5 Vanderbilt University Medical Center,, Nashville, United States
6 Hospital of the University of Pennsylvania, Philadelphia, United States
7 University of Indiana School of Medicine, Indiana, United States
8 Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel, Tel Aviv Sourasky University Medical Center, Tel Aviv, Israel

Background

Longitudinal monitoring of T- and B-cell dynamics during treatment of B-cell non-Hodgkin lymphoma (B-NHL) is clinically relevant, particularly with anti-CD20 antibodies and T-cell–engaging therapies. However, routine monitoring is limited because complete blood count (CBC)-derived absolute lymphocyte count (ALC) does not distinguish lymphocyte subsets, while flow cytometry requires specialized reagents, sample preparation, and expert analysis. We evaluated PhenoTA, an automated label-free Raman spectroscopy system with a unique CaF2 flow chamber that acquires intracellular spectral signatures directly from unmodified whole blood and classifies mature T, B, and NK lymphocytes within a CBC-aligned workflow, extending the conventional 5-part differential with lymphocyte-subset information.

Methods

Serial whole-blood samples were collected longitudinally from patients with B-NHL (including diffuse large B-cell lymphoma, follicular lymphoma) before and during active therapy (IRB No. TLV-0271-24). Samples were analyzed in parallel using conventional flow cytometry and the automated PhenoTA Raman spectroscopy platform. Raman-derived lymphocyte subset measurements were compared with matched flow cytometry as the reference method. Longitudinal changes in ALC and T- and B-cell composition were assessed across treatment cycles.

Results

Ninety-one serial blood samples from 25 patients with B-NHL were analyzed, with a minimum of three longitudinal samples per patient. Raman-derived lymphocyte subset measurements demonstrated strong agreement with matched flow cytometry, with R²=0.988 for B cells and R²=0.976 for T cells. Patients were stratified into two cohorts based on therapeutic regimen: (1) Anti-CD20 monoclonal antibodies (rituximab or obinutuzumab, with /without chemotherapy) and (2) Bispecific antibodies (mosunetuzumab, glofitamab, or epcoritamab). Across treatment regimens, Raman spectroscopy consistently identified substantial B-cell depletion that was not reliably reflected by ALC trends alone. Among patients receiving anti-CD20-based therapy, B-cell counts declined by a median of 86–99%, despite heterogeneous ALC trajectories, while concurrent T-cell contraction or expansion was readily quantified. In patients receiving bispecific antibodies, Raman monitoring detected near-complete B-cell depletion together with dynamic T-cell responses. In two patients with rising ALC, Raman spectroscopy captured 98% B-cell depletion alongside a 76% T-cell expansion within 21 days of baseline in patient 1 and, who a 98% reduction in B cells and a 246% increase in absolute T-cell count by day 22, from 1.3 to 3.3 × 10?/L in patient 2 who has received epcoritamab with rituximab and lenalidomide. Both patients subsequently achieved complete response.

Conclusions

Automated label-free Raman spectroscopy accurately quantified circulating T- and B-cell subsets directly from whole blood and demonstrated excellent agreement with flow cytometry. Longitudinal monitoring revealed clinically relevant immune dynamics that were not captured by ALC alone, including treatment-associated B-cell depletion and T-cell expansion. By eliminating antibody staining, incubation, and manual gating, this approach has the potential to integrate lymphocyte-subset analysis into routine hematology workflows and expand access to scalable longitudinal immune monitoring without repeated flow cytometry tests.

Irit Avivi Mazza, MD: Takeda - Honoraria; Medison - Honoraria; Novartis - Honoraria; AbbVie Inc. - Honoraria; MSD - Honoraria; Gilead - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); PhenoTA - Consultancy (Includes expert testimony)